Genetic Susceptibility to Neonatal Group B Streptococcal Disease
Alessandro Borghesi, Fellay lab, EPFL
mardi, 10 janvier 2017
Group B streptococcus (GBS) or Streptococcus agalactiae, a Gram positive β-hemolytic bacterium, is one of the most common pathogens causing neonatal sepsis. The incidence of GBS disease is higher in the neonatal period compared to other age groups. However, even in the absence of maternal intrapartum prophylaxis, only a small proportion of healthy full-term newborn infants exposed to GBS develops overt disease. This observation suggests that host determinants play a major role in determining individual susceptibility. Monogenic conditions underlying inborn errors of immunity have been shown to contribute to susceptibility to infectious diseases during infancy and childhood. Our aim is to test the hypothesis that rare or novel genetic variants causing single-gene inborn errors of the protective immunity to GBS contribute to individual susceptibility to GBS. Conclusion: Further investigations, including additional ltering, prioritization, case-control analyses and pathway analyses are required to identify the best candidate variants for functional follow up. Experimental validation will be necessary to confirm the causative role of the prioritized genetic variants in the susceptibility to GBS.